Previous 10 | Next 10 |
Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit ASCO Update Conference Call and Webcast at 12 p.m. ET...
Iovance Biotherapeutics (IOVA) announces positive clinical data for lifileucel in combination with pembrolizumab in patients with advanced melanoma.In the study, 86% Overall Response Rate ((ORR)) and 43% Complete Response Rate in Immune Checkpoint Inhibitor ((ICI)) Naïve Advanced Me...
86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best Response of Stable Disease ...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
As the FDA is requesting additional potency assay data, the potential lifileucel approval for melanoma will be delayed. Despite recent uncertainty, Iovance made a huge comeback due to the superb data for its lead franchise, lifileucel. I believe Iovance has more value than meets t...
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) traded today at a new 52-week low of $17.49. Approximately 2.6 million shares have changed hands today, as compared to an average 30-day volume of 2 million shares. Iovance Biotherapeutics Inc. has overhead space with shares priced $17.56, or 33...
Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonable prices for biotech companies, according to Jefferies analyst Michael Yee."Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) have been on a roller-coaster ride over the past few days. That's likely because investors don't know what to make of press releases that don't quite jibe with a big disclosure the company recently made regarding CEO Maria Fardis. ...
Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) traded today at $17.36, breaking its 52-week low. So far today approximately 2.6 million shares have been exchanged, as compared to an average 30-day volume of 2 million shares. Iovance Biotherapeutics Inc. share prices have moved betw...
Buy Dexcom, Abiomed, and Eargo on the dip: William BlairDexCom (DXCM), Abiomed (ABMD), and Eargo (EAR) have underperformed in the year so far, but citing their quarterly reports, William Blair’s Margaret Kaczor thinks the group of med-tech stocks are attractive buys on the pullback.Des...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...